Biological distribution of 131I-labeled anti-nucleus antigen monoclonal antibody chTNT in patients with pulmonary metastases from differentiated thyroid carcinoma

Phase I/II trial of 131I-MN-14 F(ab)2 an

Phase I/II trial of 131I-MN-14 F(ab)2 anti–carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

✍ Malik E. Juweid; George Hajjar; Lawrence C. Swayne; Robert M. Sharkey; Samer Sul 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 1 views

## BACKGROUND. Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131 I-MN-14 F(ab